Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
US11369658B2 · kind B2 · utility
1Cited by
17References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 25, 2021 |
| Grant date | Jun 28, 2022 |
| Priority date | — |
| Expiry date | Jun 25, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/77
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.